Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0T5LQ
|
||||
Former ID |
DIB000872
|
||||
Drug Name |
123-Iodine-labeled MFE-23
|
||||
Synonyms |
CEA antibody program (cancer/imaging); MFE-23-albumin fusion protein; CEA antibody program (cancer/imaging), Cancer Research Technology/UCL/Novozymes Delta; Albumin-linked anti-CEA single chain antibody fragment (cancer), UCL/CRT/Novozymes; Anti-CEA scFv-albumin fusion (cancer), UCL/CRT/Novozymes; 123-Iodine-labeledMFE-23; 125-I-labeled MFE-23-his; 125-Iodine-labeled MFE-23; 99mTc-labeled MFE-23
|
||||
Drug Type |
Antibody
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [530224] | ||
Company |
University College London
|
||||
Target and Pathway | |||||
Target(s) | Carcinoembryonic antigen-related cell adhesion molecule 5 | Target Info | [543999] | ||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.